Eledon Pharmaceuticals, Inc.
ELDN
$3.54
-$0.16-4.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.54M | 16.98M | 19.76M | 19.65M | 19.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.47M | 83.25M | 86.46M | 87.90M | 77.67M |
| Operating Income | -86.47M | -83.25M | -86.46M | -87.90M | -77.67M |
| Income Before Tax | -78.11M | -45.58M | -79.36M | 15.07M | -18.62M |
| Income Tax Expenses | 35.00K | 35.00K | 431.00K | 431.00K | 431.00K |
| Earnings from Continuing Operations | -78.15 | -45.62 | -79.79 | 14.64 | -19.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.15M | -45.62M | -79.79M | 14.64M | -19.05M |
| EBIT | -86.47M | -83.25M | -86.46M | -87.90M | -77.67M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.83 | -0.56 | -1.13 | 1.00 | -0.37 |
| Normalized Basic EPS | -0.52 | -0.35 | -0.68 | 0.39 | -0.18 |
| EPS Diluted | -0.83 | -0.56 | -1.13 | -1.19 | -2.56 |
| Normalized Diluted EPS | -0.52 | -0.35 | -0.68 | 0.33 | -0.24 |
| Average Basic Shares Outstanding | 362.99M | 327.69M | 301.63M | 276.42M | 241.89M |
| Average Diluted Shares Outstanding | 362.99M | 327.69M | 301.63M | 279.95M | 245.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |